Growth factors: setting the framework

References

 1. Wade N. Guillemin and Schally: the years in the wilderness. Science. 1978;200:279–282.

 2. Wade N. Guillemin and Schally: the three-lap race to Stockholm. Science. 1978;200:411–415.

 3. Wade N. Guillemin and Schally: a race spurred by rivalry. Science. 1978;200:510–513.

 4. Ellermann V, Bang O. Experimentelle leukämie bei hünern. Zentr Bakteriol Parasitenk. 1908;4:595–609.

 5. Warthin AS. Trans Assoc Am Physicians. 1904;19:421.

 6. Warthin AS. Leukemia of the common fowl. J Infect Diseases. 1907;4:369–380.

 7. Rous P. A transmissable avian neoplasm. (Sarcoma of the common fowl). J Exp Med. 1910;12:696–705.

 8. Erikson RL, Purchio AF, Erikson E, Collett MS, Brugge JS. Molecular events in cells transformed by Rous Sarcoma virus. J Cell Biol. 1980;87:319–325.

 9. Hunter T, Sefton BM. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci U S A. 1980;77:1311–1315.

10.Rous P. Comment. Proc Natl Acad Sci U S A. 1967;58:843–845.

11.Levi Montalcini R. In Praise of Imperfection, My Life and Work (translation by L Attardi of Elogio dell’imperfezione). New York: Basic Books; 1988.

12.Levi-Montalcini R. The Saga of the Nerve Growth Factor: Preliminary studies, Discovery, Further Development. Singapore: World Scientific Publishing; 1997.

13.Hamburger V. Hans Spemann and the organizer concept. Experientia. 1969;25:1121–1125.

14.Hamburger V, Levi-Montalcin R. Proliferation, differentiation and degeneration in the spinal ganglia of the chick embryo under normal and experimental conditions. J Exp Zool. 1949;111:457–502.

15.Levi-Montalcini R. The origin and development of the visceral system in the spinal cord of the chick embryo. J Morphology. 1950;86:253–283.

16.Bueker ED. Implantation of tumors in the hind limb field of the embryonic chick and the developmental response of the lumbosacral nervous system. Anat Record. 1948;102:369–389.

17.Cohen S, Levi-Montalcini R. A nerve-growth stimulating factor isolated from snake venom. Proc Natl Acad Sci U S A. 1958;42:571–574.

18.Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol. 1964;12:394–407.

19.Cohen S. Nobel lecture. Epidermal growth factor. Biosci Rep. 1986;6: 1017–1028.

20.Gregory H. Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nature. 1975;257:325–327.

21.Ushiro H, Cohen S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J Biol Chem. 1980;255:8363–8365.

311

Signal Transduction

22.Downward J, Yarden Y, Mayes E, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature. 1984;307:521–527.

23.Carrel A. On the permanent life of tissues outside of the organism. J Exp Med. 1912:516–528.

24.Ross R, Vogel A. The platelet-derived growth factor. Cell. 1978;14:203–210.

25.Hamilton D. The Monkey Gland Affair. London: Chatto & Windus; 1986.

26.Ross R, Glomset J, Kariya B, Harker L. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A. 1974;71:1207–1210.

27.Antoniades HN, Scher CD, Stiles CD. Purification of human plateletderived growth factor. Proc Natl Acad Sci U S A. 1979;76:1809–1813.

28.Cooper JA, Bowen PD, Raines E, Ross R, Hunter T. Similar effects of platelet-derived growth factor and epidermal growth factor on the phosphorylation of tyrosine in cellular proteins. Cell. 1982;31:263–273.

29.Doolittle RF, Hunkapiller MW, Hood LE, et al. Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a plateletderived growth factor. Science. 1983;221:275–277.

30.Waterfield MD, Scrace GT, Whittle N, et al. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature. 1983;304:35–39.

31.Robbins KC, Antoniades HN, Devare SG, Hunkapiller MW, Aaronson SA. Structural and immunological similarities between simian sarcoma virus gene product(s) and human platelet-derived growth factor. Nature. 1983;305:605–608.

32.Theilen GH, Gould D, Fowler M, Dungworth DL. C-type virus in tumor tissue of a woolly monkey (Lagothrix spp.) with fibrosarcoma. J Natl Cancer Inst. 1971;47:881–889.

33.De Larco JE, Todaro GJ. Growth factors from murine sarcoma virustransformed cells. Proc Natl Acad Sci U S A. 1978;75:4001–4005.

34.Childs CB, Proper JA, Tucker RF, Moses HL. Serum contains a plateletderived transforming growth factor. Proc Natl Acad Sci U S A. 1982;79:5312–5316.

35.Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. Type transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci U S A. 1985;82:119–123.

36.Sporn MB, Roberts AB, Wakefield LM, de-Crombrugghe B. Some recent advances in the chemistry and biology of transforming growth factor- . J Cell Biol. 1987;105:1039–1045.

37.Roberts AB, Lamb LC, Newton DL, Sporn MB, De Larco JE, Todaro GJ. Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci U S A. 1980;77:3494–3498.

312

Growth factors: setting the framework

38.Kaplan DR, Chao FC, Stiles CD, Antoniades HN, Scher CD. Platelet granules contain a growth factor for fibroblasts. Blood. 1979;53:1043– 1052.

39.Grotendorst GR, Chang T, Seppa HE, Kleinman HK, Martin GR. Plateletderived growth factor is a chemoattractant for vascular smooth muscle cells. J Cell Physiol. 1982;113:261–266.

40.Cone JL, Brown DR, DeLarco JE. An improved method of purification of transforming growth factor, type from platelets. Anal Biochem. 1988;168:71–74.

41.Haines KA, Kolasinski SL, Cronstein BN, Reibman J, Gold LI, Weissmann G. Chemoattraction of neutrophils by substance P and transforming growth factor- 1 is inadequately explained by current models of lipid remodeling. J Immunol. 1993;151:1491–1499.

42.Postlethwaite AE, Keski Oja J, Moses HL, Kang AH. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor . J Exp Med. 1987;165:251–256.

43.Nathan C, Sporn M. Cytokines in context. J Cell Biol. 1991;113:981–986.

44.Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.

45.Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364.

46.Johnsen M, Lund LR, Romer J, Almholt K, Dano K. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol. 1998;10:667–671.

47.Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res. 1997;237:7–13.

48.Evan G, Littlewood T. A matter of life and cell death. Science. 1998;281:1317–1322.

49.Prescott JC, Blackburn EH. Telomerase: Dr Jekyll or Mr Hyde? Curr Opin Genet Dev 1999;9:368–373.

50.Murphy KL, Rosen JM. Mutant p53 and genomic instability in a transgenic mouse model of breast cancer. Oncogene. 2000;19:1045–1051.

51.Iiri T, Farfel Z, Bourne HR. G-protein diseases furnish a model for the turnon switch. Nature. 1998;394:35–38.

52.Weitzman JB, Yaniv M. Rebuilding the road to cancer. Nature. 1999;400:401–402.

53.Futreal PA, Coin L, Marshall M, Down T, hubbard T, Wooster R, Rahman N, Stratton MR. A census of human cancer genes. Nature Rev Cancer. 2004;4:177–183.

313